Pure Global AI
NCT06354816Not yet recruiting

VENLID: The Application of a 10%-Lidocaine Spray Prior to the Insertion of a Peripheral Intra-venous Catheter in Female Adults

VENLID: A Prospective, Randomized, Double-blind, Controlled Trial on the Application of a 10%-Lidocaine Spray Prior to the Insertion of a Peripheral Intra-venous Catheter in Female Adults
Krankenhaus Barmherzige Schwestern LinzPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pain
Drug/Device/Intervention
Xylocaine 10% pump spray
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Krankenhaus Barmherzige Schwestern Linz
Timeline & enrollment
Phase
Phase 4
Start date
May 01, 2024
End date
May 01, 2024
Enrollment
40 participants
Primary outcome

To demonstrate a reduction of pain caused by PIVC rated by Numerical Rating Scale (NRS), after application of a 10% lidocaine spray- Separately measured for the plantar side of the hand/vessel at the dorsum manus, and for the forearm/cubita

Summary

Volunteers are invited to undergo 4 insertions of a peripheral intra-venous 18-gauge catheter
 (PIVC); 2 insertions at the the start of the study on the plantar side of the hand/vessel at
 the dorsum manus, 2 insertions after 2-10 hours into the forearm/cubita with and without
 application of a 10-% lidocaine spray (5 hubs of xylocaine 10%-pump spray; AstraZeneca BV,
 Zoetermeer, The Netherlands) prior to the insertion of the PIVC.

ICD-10 classifications
Pain, unspecifiedPain, not elsewhere classifiedPain in limbAcute painOther chronic pain
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06354816
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06354816 through Pure Global AI's free database. This Phase 4 trial is sponsored by Krankenhaus Barmherzige Schwestern Linz and is currently Not yet recruiting. The study focuses on Pain. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.